The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B (vol 71, pg 281, 2016)

被引：0
|
作者：
Solomon, M.
Schechter, M.
Liu, A. Y.
机构：
来源：
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2016年 / 72卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：E82 / E82
页数：1
相关论文
共 50 条
  • [21] Pill related oesophagitis due to tenofovir disproxil fumarate/emtricitabine (Truvada) HIV pre-exposure prophylaxis
    Bonnichsen, Mark H.
    Tschuchnigg, Mark
    Post, Jeffrey J.
    Bye, William
    INTERNAL MEDICINE JOURNAL, 2022, 52 (06) : 1099 - 1100
  • [22] Emtricitabine/Tenofovir Disoproxil Fumarate: A Review of its Use in HIV-1 Pre-Exposure Prophylaxis
    Greg L. Plosker
    Drugs, 2013, 73 : 279 - 291
  • [23] Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals
    Okwundu, Charles I.
    Uthman, Olalekan A.
    Okoromah, Christy A. N.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (07):
  • [24] A Subcutaneous Biodegradable Implant for Sustained Delivery of Tenofovir Alafenamide (TAF) for HIV Pre-exposure Prophylaxis (PrEP)
    Girouard, Natalie
    Johnson, Leah
    Luecke, Ellen
    Demkovich, Zach
    Jester, Teresa
    Li, Alice
    Johnson, Pafio
    van der Straten, Ariane
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2018, 34 : 107 - 107
  • [25] Safety, Adherence and Acceptability of Intermittent Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis (PrEP) among HIV-Uninfected Ugandan Volunteers Living in HIV-Serodiscordant Relationships: A Randomized, Clinical Trial
    Kibengo, Freddie M.
    Ruzagira, Eugene
    Katende, David
    Bwanika, Agnes N.
    Bahemuka, Ubaldo
    Haberer, Jessica E.
    Bangsberg, David R.
    Barin, Burc
    Rooney, James F.
    Mark, David
    Chetty, Paramesh
    Fast, Patricia
    Kamali, Anatoli
    Priddy, Frances H.
    PLOS ONE, 2013, 8 (09):
  • [26] InterPrEP: internet-based pre-exposure prophylaxis (PrEP) with generic tenofovir DF/emtricitabine (TDF/FTC) in London -analysis of pharmacokinetics, safety and outcomes
    Wang, Xinzhu
    Nwokolo, Nneka
    Korologou-Linden, Roxanna
    Hill, Andrew
    Whitlock, Gary
    Day-Weber, Isaac
    McClure, Myra
    Boffito, Marta
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [27] InterPrEP (II): internet-based pre-exposure prophylaxis (PrEP) with generic tenofovir DF/emtricitabine (TDF/FTC) in London: analysis of safety and outcomes
    Aloysius, I.
    Zdravkov, J.
    Whitlock, G.
    Alldis, J.
    Nwokolo, N.
    Aylward, A.
    Arvind, A.
    Wang, X.
    Day-Weber, I.
    McClure, M.
    Boffito, M.
    Smith, R.
    Houghton-Price, V.
    Hill, A.
    HIV MEDICINE, 2017, 18 : 25 - 25
  • [28] Pre-exposure prophylaxis (PrEP) in HIV-uninfected individuals with high-risk behaviour
    Nadery, S.
    Geerlings, S. E.
    NETHERLANDS JOURNAL OF MEDICINE, 2013, 71 (06): : 295 - 299
  • [29] Phase 3 randomized, controlled DISCOVER study of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP): week 96 results
    Ruane, P. J.
    Clarke, A.
    Post, F. A.
    Schembri, G.
    Jessen, H.
    Trottier, B.
    Bergin, C.
    Molina, J-M
    Wong, P.
    Ebrahimi, R.
    Brainard, D. M.
    Osinusi, A.
    Das, M.
    McCallister, S.
    HIV MEDICINE, 2019, 20 : 95 - 96
  • [30] Performance and Stability of Tenofovir Alafenamide Formulations within Subcutaneous Biodegradable Implants for HIV Pre-Exposure Prophylaxis (PrEP)
    Li, Linying
    Johnson, Leah M.
    Krovi, Sai Archana
    Demkovich, Zach R.
    van der Straten, Ariane
    PHARMACEUTICS, 2020, 12 (11) : 1 - 17
12345